New heart ablation tool could cut radiation and costs

NCT ID NCT07130773

Recruiting now Symptom relief Sponsor: Cardiocentro Ticino Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new second-generation catheter (FARAWAVE Nav) used without a pre-procedure CT scan to the standard approach with a CT scan for treating atrial fibrillation. The goal is to see if the new method reduces radiation exposure and procedure time. 58 adults with atrial fibrillation who are candidates for ablation will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FARAWAVE Nav PFA catheter (second-generation pulsed field ablation device)
What this could lead to: If successful, this approach could reduce radiation exposure and costs for atrial fibrillation ablation procedures.
What could go wrong: This is a small, early-stage trial with only 58 participants. The new catheter may not perform as well as the standard method, and long-term outcomes are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF) ATRIAL FIBRILLATION ABLATION PULSED-FIELD ABLATION

Contacts and locations

Locations

Cardiocentro Ticino - Ente Ospedaliero Cantonale
RECRUITING

Lugano, Canton Ticino, 6900, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.